BO-112 not checked
Highlight Therapeutics · anti-PD1 monoclonal antibody
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection”In the company’s words, NCT06422936 on ClinicalTrials.gov
- Tested for
- Basal Cell Carcinoma
- Main trialPhase 2
- “This is a multicenter, phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability, pharmacodynamics and preliminary efficacy of intra-lesional BO-112 in patients with resectable primary low and high risk basal cell carcinoma. * primary endpoint is composite visual and pathological response \[at surgery\] on patient level as assessed by central review * secondary endpoints are 1. Occurrence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation or death on patient level. 2. Pathological response \[at surgery\] on patient…”In the company’s words, NCT06422936 on ClinicalTrials.gov
- Other names
- anti-PD1 monoclonal antibody
Other drugs for Basal Cell Carcinoma
- STAR0602Marengo Therapeutics, Inc. · Phase 1/2
- MDNA11Medicenna Therapeutics, Inc. · Phase 1/2
- PembrolizumabMerck & Co. · Phase 1/2
- Vusolimogene OderparepvecReplimune, Inc. · Phase 1/2
- CemiplimabRegeneron · Phase 2
- FianlimabRegeneron · Phase 2
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Dec 2026 | Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) | |
| Phase 1Completed | Jul 2020 | Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026